dc.contributor.author |
Coleman, D |
|
dc.contributor.author |
Rosoff, P |
|
dc.date.accessioned |
2020-08-07T15:10:23Z |
|
dc.date.available |
2020-08-07T15:10:23Z |
|
dc.date.issued |
2020 |
|
dc.identifier.issn |
2053-9711 |
|
dc.identifier.uri |
https://hdl.handle.net/10161/21293 |
|
dc.description.abstract |
<jats:title>Abstract</jats:title>
<jats:p>The COVID-19 pandemic represents a major challenge to both technologically
advanced and resource-poor countries. There are currently no effective treatments
for severe disease other than supportive care and advanced life support measures,
including the use of mechanical ventilators. With the urgency and necessity bred from
desperation, there have been many calls to utilize unproven therapies, such as hydroxychloroquine,
for which little evidence of efficacy exists. We have previously argued that such
off-label use, while legal, is problematic (and even dangerous) and have suggested
several regulatory remedies that could protect patients and advance their interests
while preserving the reasonable authority of physicians to do what they and their
patients think is the best course of action. In this essay we ask whether the special
conditions existing in a public healthcare crisis, such as the current pandemic, would
justify a relaxing of our argument and permit ongoing unregulated off-label use. We
outline at least four areas of concern, all of which can be exacerbated by the widespread
distress and despair amongst doctors, patients and other stakeholders. We contend
that, if anything, these conditions warrant even more caution and scrutiny of this
practice.</jats:p>
|
|
dc.language |
en |
|
dc.publisher |
Oxford University Press (OUP) |
|
dc.relation.ispartof |
Journal of Law and the Biosciences |
|
dc.relation.isversionof |
10.1093/jlb/lsaa031 |
|
dc.title |
The Enhanced Danger of Physicians’ Off-Label Prescribing During a Public Health Emergency |
|
dc.type |
Journal article |
|
duke.contributor.id |
Coleman, D|0136486 |
|
duke.contributor.id |
Rosoff, P|0099553 |
|
dc.date.updated |
2020-08-07T15:10:22Z |
|
pubs.organisational-group |
Duke Law School |
|
pubs.organisational-group |
Center for Child and Family Policy |
|
pubs.organisational-group |
Duke Science & Society |
|
pubs.organisational-group |
Duke |
|
pubs.organisational-group |
Sanford School of Public Policy |
|
pubs.organisational-group |
Initiatives |
|
pubs.organisational-group |
Institutes and Provost's Academic Units |
|
pubs.organisational-group |
School of Medicine |
|
pubs.organisational-group |
Pediatrics, Hematology-Oncology |
|
pubs.organisational-group |
Pediatrics |
|
pubs.organisational-group |
Clinical Science Departments |
|
pubs.publication-status |
Published |
|